RJA
NAGE

Raymond James & Associates’s Niagen Bioscience NAGE Stock Holding History

Raymond James & Associates’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,001
Closed -$168K – 3685
2018
Q1 		$168K Buy
+40,001
New +$209K ﹤0.01% 3183

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Raymond James & Associates's NAGE Position: Q2 2018 in Review

Raymond James & Associates sold out of Niagen Bioscience (NAGE) in Q2 2018, closing a stake of 40,001 shares — an estimated $168K sold.

Raymond James & Associates first reported a position in NAGE in Q1 2018 and held it in 1 quarter. The position peaked at $168K in Q1 2018. 64 funds tracked by Wall St. Rank hold NAGE as of Q2 2018.

  • Raymond James & Associates reported no remaining Niagen Bioscience position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 40,001 Niagen Bioscience shares in Q2 2018, an estimated $168K.
  • Raymond James & Associates first reported a position in Niagen Bioscience in Q1 2018 and held it in 1 quarter.
  • Raymond James & Associates's Niagen Bioscience position peaked at $168K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.